BR112022016604A2 - Compostos para uso em infecções virais - Google Patents
Compostos para uso em infecções viraisInfo
- Publication number
- BR112022016604A2 BR112022016604A2 BR112022016604A BR112022016604A BR112022016604A2 BR 112022016604 A2 BR112022016604 A2 BR 112022016604A2 BR 112022016604 A BR112022016604 A BR 112022016604A BR 112022016604 A BR112022016604 A BR 112022016604A BR 112022016604 A2 BR112022016604 A2 BR 112022016604A2
- Authority
- BR
- Brazil
- Prior art keywords
- compounds
- viral infections
- virus
- viral
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K11/00—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K11/02—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof cyclic, e.g. valinomycins ; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/15—Depsipeptides; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Transplantation (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20382152 | 2020-03-02 | ||
| EP20382192 | 2020-03-13 | ||
| EP20382266 | 2020-04-02 | ||
| EP20382339 | 2020-04-27 | ||
| EP20382815 | 2020-09-16 | ||
| EP20382816 | 2020-09-16 | ||
| EP21382059 | 2021-01-25 | ||
| PCT/EP2021/055147 WO2021175831A2 (en) | 2020-03-02 | 2021-03-02 | Compounds for use in viral infections |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022016604A2 true BR112022016604A2 (pt) | 2022-10-11 |
Family
ID=74732953
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022016604A BR112022016604A2 (pt) | 2020-03-02 | 2021-03-02 | Compostos para uso em infecções virais |
| BR112022016675A BR112022016675A2 (pt) | 2020-03-02 | 2021-03-02 | Compostos para uso em condições inflamatórias |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022016675A BR112022016675A2 (pt) | 2020-03-02 | 2021-03-02 | Compostos para uso em condições inflamatórias |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US20230159594A1 (https=) |
| EP (2) | EP4114433A2 (https=) |
| JP (2) | JP2023517536A (https=) |
| KR (2) | KR20220151643A (https=) |
| CN (2) | CN115461067A (https=) |
| AU (2) | AU2021232535A1 (https=) |
| BR (2) | BR112022016604A2 (https=) |
| CA (2) | CA3169540A1 (https=) |
| CL (2) | CL2022002396A1 (https=) |
| CO (2) | CO2022014093A2 (https=) |
| IL (2) | IL296069A (https=) |
| MX (2) | MX2022010926A (https=) |
| PE (2) | PE20230606A1 (https=) |
| PY (2) | PY2117301A (https=) |
| TW (2) | TWI908772B (https=) |
| UY (2) | UY39109A (https=) |
| WO (2) | WO2021175831A2 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230158102A1 (en) * | 2020-03-02 | 2023-05-25 | Pharma Mar, S.A. | Compounds for use in the treatment of coronavirus infection |
| CN115461067A (zh) * | 2020-03-02 | 2022-12-09 | 法马马有限公司 | 用于炎症的化合物 |
| AU2021231521A1 (en) * | 2020-03-02 | 2022-10-06 | Pharma Mar, S.A. | PLD for use in combination in the treatment of coronavirus |
| WO2024165764A1 (en) * | 2023-02-10 | 2024-08-15 | Pharma Mar, S.A. | Plitidepsin for use in the treatment of non-integrated dna viral infections |
| CN117285611B (zh) * | 2023-11-24 | 2024-02-09 | 中国海洋大学 | 一种来源于海鞘的抗炎寡肽及其在制备药物中的应用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8922026D0 (en) * | 1989-09-29 | 1989-11-15 | Pharma Mar Sa | Novel anti-viral and cytotoxic agent |
| US6156724A (en) * | 1996-06-07 | 2000-12-05 | Rinehart; Kenneth L. | Uses of didemnins as immunomodulating agents |
| GB9803448D0 (en) | 1998-02-18 | 1998-04-15 | Pharma Mar Sa | Pharmaceutical formulation |
| WO1999052515A2 (de) * | 1998-04-14 | 1999-10-21 | Hassan Jomaa | Verwendung von phosphororganischen verbindungen zur therapeutischen und prophylaktischen behandlung von infektionen |
| CA2405779A1 (en) | 2000-04-07 | 2001-10-18 | The Trustees Of The University Of Pennsylvania | Tamandarin and didemnin analogs and methods of making and using them |
| UA76718C2 (uk) | 2000-06-30 | 2006-09-15 | Фарма Мар, С.А. | Протипухлинні похідні аплідину |
| DK1347743T3 (da) * | 2000-12-07 | 2006-07-03 | Univ Utrecht Holding Bv | Præparat til behandling af inflammatoriske lidelser |
| EP1596823A2 (en) * | 2003-02-21 | 2005-11-23 | Sun Pharmaceuticals Industries Ltd. | A stable ophthalmic composition |
| JP2006523214A (ja) | 2003-03-21 | 2006-10-12 | ジユーリー，マデレーン・エム | タマンダリン類似物およびこれらのフラグメントそして製造方法および使用方法 |
| WO2007101235A2 (en) * | 2006-02-28 | 2007-09-07 | Pharma Mar, S.A. | Improved antitumoral treatments |
| WO2011020913A2 (en) | 2009-08-21 | 2011-02-24 | Pharma Mar, S.A. | Cyclodepsipeptide antiviral compounds |
| BR112012014624A8 (pt) * | 2009-12-15 | 2017-12-26 | Novartis Ag | suspensão homogênea de compostos de imunopotenciação e usos dos destes |
| US20120040033A1 (en) * | 2010-08-10 | 2012-02-16 | Ernest Timothy Armstrong | Anti-infective mangrove extract against viruses, bacteria and fungi |
| GB201316524D0 (en) * | 2013-09-17 | 2013-10-30 | Medical Res Council | Biomarkers |
| JP2017526728A (ja) * | 2014-09-15 | 2017-09-14 | インフラマトリー・レスポンス・リサーチ・インコーポレイテッド | 炎症介在性状態の治療におけるレボセチリジン及びモンテルカスト |
| US11771739B2 (en) * | 2017-06-16 | 2023-10-03 | Vanderbilt University | Methods and compositions for treating microbial inflammation |
| CN115461067A (zh) * | 2020-03-02 | 2022-12-09 | 法马马有限公司 | 用于炎症的化合物 |
-
2021
- 2021-03-02 CN CN202180018363.6A patent/CN115461067A/zh active Pending
- 2021-03-02 BR BR112022016604A patent/BR112022016604A2/pt unknown
- 2021-03-02 WO PCT/EP2021/055147 patent/WO2021175831A2/en not_active Ceased
- 2021-03-02 EP EP21708019.1A patent/EP4114433A2/en active Pending
- 2021-03-02 CA CA3169540A patent/CA3169540A1/en active Pending
- 2021-03-02 PE PE2022001795A patent/PE20230606A1/es unknown
- 2021-03-02 WO PCT/EP2021/055187 patent/WO2021175857A1/en not_active Ceased
- 2021-03-02 AU AU2021232535A patent/AU2021232535A1/en active Pending
- 2021-03-02 IL IL296069A patent/IL296069A/en unknown
- 2021-03-02 PY PY202102117301A patent/PY2117301A/es unknown
- 2021-03-02 KR KR1020227034317A patent/KR20220151643A/ko active Pending
- 2021-03-02 JP JP2022552946A patent/JP2023517536A/ja active Pending
- 2021-03-02 PY PY202102117308A patent/PY2117308A/es unknown
- 2021-03-02 BR BR112022016675A patent/BR112022016675A2/pt unknown
- 2021-03-02 MX MX2022010926A patent/MX2022010926A/es unknown
- 2021-03-02 TW TW110107293A patent/TWI908772B/zh active
- 2021-03-02 KR KR1020227034280A patent/KR20220150350A/ko active Pending
- 2021-03-02 US US17/908,533 patent/US20230159594A1/en active Pending
- 2021-03-02 PE PE2022001880A patent/PE20230412A1/es unknown
- 2021-03-02 UY UY0001039109A patent/UY39109A/es unknown
- 2021-03-02 TW TW110107292A patent/TW202144381A/zh unknown
- 2021-03-02 JP JP2022552937A patent/JP2023517535A/ja active Pending
- 2021-03-02 AU AU2021231197A patent/AU2021231197A1/en active Pending
- 2021-03-02 EP EP21708237.9A patent/EP4114435A1/en active Pending
- 2021-03-02 IL IL296068A patent/IL296068A/en unknown
- 2021-03-02 CN CN202180018734.0A patent/CN115666616A/zh active Pending
- 2021-03-02 UY UY0001039110A patent/UY39110A/es unknown
- 2021-03-02 CA CA3169544A patent/CA3169544A1/en active Pending
- 2021-03-02 US US17/908,526 patent/US20230295236A1/en active Pending
- 2021-03-02 MX MX2022010921A patent/MX2022010921A/es unknown
-
2022
- 2022-09-02 CL CL2022002396A patent/CL2022002396A1/es unknown
- 2022-09-02 CL CL2022002395A patent/CL2022002395A1/es unknown
- 2022-09-30 CO CONC2022/0014093A patent/CO2022014093A2/es unknown
- 2022-09-30 CO CONC2022/0014031A patent/CO2022014031A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022016604A2 (pt) | Compostos para uso em infecções virais | |
| MX2021014742A (es) | Peptidomimeticos para el tratamiento de infecciones por coronavirus y picornavirus. | |
| BR112022000503A2 (pt) | Compostos úteis para tratar infecções por vírus influenza | |
| BR112022018819A2 (pt) | Vacinas contra coronavírus e métodos de uso | |
| BR112018014794A2 (pt) | pirimidinas substituídas com arila para uso em infecção pelo vírus influenza | |
| GT201300093A (es) | Compuestos antivirales | |
| CL2017001798A1 (es) | Compuestos de pirazina para el tratamiento de enfermedades infecciosas. | |
| BR122020003634B8 (pt) | uso de nitazoxanida, tizoxanida ou sal farmaceuticalmente aceitável do mesmo no tratamento de uma doença semelhante a influenza | |
| CL2016000493A1 (es) | Inhibidores de polimerasa hcv. | |
| BR112017004524A2 (pt) | pirrolopirimidinas para uso na infecção pelo vírus da gripe | |
| BR112017002370A2 (pt) | indóis para uso na infecção pelo vírus da gripe | |
| CL2015003615A1 (es) | Nucleósidos sustituidos, nucleótidos y análogos de los mismos. | |
| MX383447B (es) | Combinación de un inhibidor de ensamblaje de cápsido y peginterferón alfa-2a y sus usos para tratar infecciones por virus de la hepatitis b (vhb). | |
| BR112018009009A2 (pt) | terapia combinada de um inibidor de formação de capsídeo hbv e um interferon | |
| MY141003A (en) | Materials and methods for treating viral infections with a cysteamine compound | |
| MX381896B (es) | Compuestos de tiazolida para el tratamiento de infecciones virales. | |
| UY38603A (es) | Uso de virus oncolíticos para el tratamiento del cáncer | |
| BR112018010679A2 (pt) | métodos para tratar, prevenir e diagnosticar a infecção por vírus da diarréia epidêmica porcina | |
| BR112022016117A2 (pt) | Métodos para a prevenção ou o tratamento de ferimento ou falha em um órgão induzidos por vírus com dímero de il-22 | |
| BR112014003278A2 (pt) | vacinas para influenza h5 | |
| BR112014032682A2 (pt) | anticorpo monoclonal humano contra a proteína vp1 do vírus jc | |
| UY39313A (es) | Composiciones amortiguadoras para el tratamiento de infecciones virales transmitidas por el aire | |
| BR112022018529A2 (pt) | Usos de conjugado de hialuronano | |
| BR112022016653A2 (pt) | Pld para uso em combinação no tratamento de coronavírus | |
| MX379219B (es) | Uso de taurina en la prevención y/o el tratamiento de enfermedades inducidas por virus del género coronavirus y/o del género rotavirus |